ISRCTN57843703终止未知
A randomised, double-blind, placebo-controlled, dose-ranging two-centre study to evaluate the efficacy and safety of Devil's Claw in the treatment of knee and hip osteoarthritis
niversity of Southampton (UK)0 个研究点目标入组 264 人开始时间: 2006年12月13日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 终止
- 发起方
- 入组人数
- 264
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients with either a pragmatic diagnosis of:
- •1.1. Osteoarthritis of the knee, with no other known rheumatological condition and who report the following clinical features (based on the American College of Rheumatology [ACR] classification for knee OA1):
- •1.1.1. Knee pain on most days of the previous month
- •1.1.2. Morning stiffness of less than 30 minutes duration
- •1.1.3. Stiffness in resting the joint, and
- •1.1.4. Aged over 40 years
- •1.2. Osteoarthritis of the hip, with no other known rheumatological condition and who report the following clinical features (based on the ACR classification for hip OA2) - hip pain on most days of the previous month and at least two of the following three features:
- •1.2.1. Erythrocyte sedimentation rate (ESR) less than 20 mm/hour
- •1.2.2. Radiographic femoral or acetabular osteophytes
- •1.2.3. Radiographic joint space narrowing (superior, axial and/or medial), and
- •1.2.4. Aged over 45 years of age
- •The diagnosis of osteoarthritis will be confirmed by X-ray.
- •2. Only patients who have grade 2 to 4 of the Kellgren and Lawrence scale will be recruited (The Kellgren and Lawrence scale ranges from grade zero to grade four where grades zero and one represent doubtful osteoarthritic changes and therefore a doubtful diagnosis)
- •3. Patients who have been on stable medication (conventional or complementary, including nutritional medicine) for the past three months, but are still getting symptoms (incomplete responders)
- •4. Only those patients who record baseline pain scores on the WOMAC scale of at least 20 mm on the Visual Analogue Scale (VAS) for a minimum of six out of seven days monitored during the period from Clinic Visit one (screening) and Clinic Visit two (baseline)
- •5. Ability to comply with the requirements of the study and to give informed consent
- •6. For women of child-bearing potential: negative pregnancy test
排除标准
- •1. Participation in an investigational trial within 30 days prior to enrolment
- •2. Previous treatment with Devil's Claw within 90 days prior to enrolment
- •3. Patients awaiting a replacement knee or hip joint
- •4. Patients with other conditions that cause pain
- •5. Patients with congenital dislocation of the hip
- •6. Patients who have had operations on their hip due to previous trauma
- •7. Patients with severe co-morbidities - including severe cardiac or pulmonary disease and cancer
- •8. Dementia, psychoses, or other significant impairment of mental status that would prohibit sufficient comprehension, provision of informed consent and to allow undertaking of the necessary self-care or toxicity reporting
- •9. Patients taking corticosteroid medication
- •10. Known allergies against any of the ingredients of the treatments
- •11. Patients who would be unable to complete the self assessment forms, or to attend for X-ray and clinical examination
- •12. Patients with other known rheumatic disease such as rheumatoid arthritis
- •13. Patients with the diagnosis gout
- •14. Patients who report a red or hot swollen joint (which is unlikely to be due to OA), and would require further rheumatological assessment
- •15. Patients with conditions known to be contraindicated to the study medication i.e. patients with gastric or duodenal ulcers; gallstones; patients taking drugs for arrhythmias; patients with heart failure
- •16. Patients who are pregnant, trying to become pregnant or breastfeeding
研究者
相似试验
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, dose ascending, 3 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GSK233705B in COPD subjects.Study is in COPD patientsEUCTR2006-001419-30-BEGlaxoSmithKline Research and Development Ltd45
进行中（未招募）
1 期
A study of MEDI7352 in painful diabetic neuropathyPainful diabetic neuropathyMedDRA version: 20.0Level: PTClassification code 10012680Term: Diabetic neuropathySystem Organ Class: 10029205 - Nervous system disordersEUCTR2018-002523-42-ESAstraZenecaAB271
进行中（未招募）
1 期
A study of MEDI7352 in painful diabetic neuropathyEUCTR2018-002523-42-DKAstraZeneca AB272
进行中（未招募）
不适用
A randomised, double-blind, placebo-controlled, dose ascending, 3 period crossover study to examine the safety, tolerability, pharmacodynamics and pharmacokinetics of repeat inhaled doses of GSK233705B in COPD subjects.EUCTR2006-001419-30-SEGlaxoSmithKline Research and Development Ltd45
进行中（未招募）
1 期
A randomised, double-blind, placebo-controlled, dose ascending, 2-cohort, parallel group study to examine the safety, tolerability, pharmacokinetics and pharmacodynamics of twice-daily inhaled doses of GSK233705B formulated with the excipient Magnesium Stearate in COPD subjects for 7-days. - GSK233705B pk and pd study in COPD patientsStudy is in COPD patients.MedDRA version: 9.1Level: LLTClassification code 10010952Term: COPDEUCTR2006-006083-33-NLGlaxoSmithKline Research and Development Ltd